title: Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study.
abstract: OBJECTIVE
  This bioequivalence study aimed to compare rate and extent of absorption of a generic medicinal product of ibandronic acid 150-mg film-coated tablet versus Bonviva(®).
  
  
  METHODS
  This was a single-centre, open-label, randomized, three-way, three-sequence, reference-replicated, crossover bioequivalence study, under fasting conditions. A single oral dose of ibandronic acid as one 150-mg film-coated tablet was administered in each study period. Each washout period lasted 14 days. Blood samples were collected according to a predefined sampling schedule and up to 48.0 hours after administraton in each period. Plasma concentrations of ibandronic acid were measured using a liquid chromatograph-mass spectrometry/mass spectrometry method. Bioequivalence between generic and reference medicinal products is acceptable if the 90 % confidence intervals (CI) of ratio of least-squares means between the test and the reference product of ln-transformed area under the serum concentration-time curve from time zero to time of last measurable concentration (AUC0-t ) is within the 80.00-125.00 % interval. Prospectively, a scaled average bioequivalence approach for maximum serum concentration (C max) was established.
  
  
  RESULTS
  153 healthy volunteers were enrolled and randomized. After the test formulation (T) and first and second Bonviva(®) (R) dosing, the C max was 96.71 ± 90.19 ng/mL, 92.67 ± 91.48 ng/mL and 87.94 ± 60.20 ng/mL and the AUC0-t was 390.83 ± 287.27 ng·h/mL, 388.54 ± 356.76 ng·h/mL and 383.53 ± 246.72, respectively. Ratios of T/R and 90 % CI were 100.92 % (94.35-107.94) for AUC0-t , 100.90 % (94.37-107.88) for AUC0-inf and 102.56 % (95.05-110.67) for C max.
  
  
  CONCLUSIONS
  Test formulation of ibandronic acid is bioequivalent in rate and extent of absorption to Bonviva(®) following a 150-mg dose, under fasting conditions.
authors.affiliation: Medical Department, Tecnimede S.A, Zona Industrial da Abrunheira, Rua da Tapada Grande nr. 2, Abrunheira, 2710-089, Sintra, Portugal, augusto.filipe@tecnimede.pt.
authors.forename: Augusto
authors.initials: A
authors.lastname: Filipe
authors.forename: Pedro
authors.initials: P
authors.lastname: Pedroso
authors.forename: Susana
authors.initials: S
authors.lastname: Almeida
authors.forename: Rita
authors.initials: R
authors.lastname: Neves
authors.forename: Sylvie
authors.initials: S
authors.lastname: Boudreault
mesh_terms: D065567:Absorption, Physiological; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D004164:Diphosphonates / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005215:Fasting; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D000077557:Ibandronic Acid; D008297:Male; D008875:Middle Aged; D013607:Tablets; D013810:Therapeutic Equivalency; D055815:Young Adult
chemical_list: D004164:Diphosphonates; D013607:Tablets; D000077557:Ibandronic Acid
references.citation: J Clin Pharmacol. 2004 Sep;44(9):951-65
references.pmid: 15317823
references.citation: J Clin Endocrinol Metab. 2005 Sep;90(9):5018-24
references.pmid: 15972582
references.citation: Clin Pharmacokinet. 2009;48(11):725-43
references.pmid: 19817502